目的 觀察宮瘤消膠囊聯合甲睪酮和米非司酮治療絕經期子宮肌瘤的臨床療效。方法 選取2012年3月-2014年7月衡水市第二人民醫(yī)院婦科進行治療絕經期子宮肌瘤患者112例,隨機分為對照組和治療組,每組各56例。對照組患者口服甲睪酮片,1片/次,1次/d;并在睡覺前口服米非司酮片,1片/次,1次/d。治療組在對照組治療基礎上口服宮瘤消膠囊,4粒/次,3次/d。兩組均連續(xù)治療6個月。觀察兩組的臨床療效,同時比較兩組治療前后子宮體積、肌瘤體積、促卵泡激素(FSH)、孕酮(P)、雌二醇(E₂)、黃體生成素(LH)的變化情況。結果 治療后,對照組和治療組的總有效率分別為80.36%、91.07%,兩組比較差異有統計學意義(P<0.05)。治療后,兩組子宮體積、肌瘤體積均明顯縮小,兩組E₂、P、FSH水平均較治療前顯著下降,同組治療前后差異具有統計學意義(P<0.05);且治療組這些觀察指標的改善程度優(yōu)于對照組,兩組比較差異有統計學意義(P<0.05)。結論 宮瘤消膠囊聯合甲睪酮和米非司酮治療絕經期子宮肌瘤效果較好,可顯著縮小肌瘤體積,降低E₂、P、FSH水平,具有一定的臨床推廣應用價值。

Objective To observe the clinical effect of Gongliuxiao Capsules combined with methyltestosterone and mifepristone in treatment of menopause uterine fibroids. Methods Patients (112 cases) with menopause uterine fibroids in Department of Gynaecology of the Second People's Hospital of Hengshui from March 2012 to July 2014 were randomly divided into control (n=56) and treatment (n=56) groups. The patients in the control group were po administered with Methyltestosterone Tablets, 1 tablet/time, once daily. And they were po administered with Mifepristone Tablets before sleep, 1 tablet/time, once daily. The patients in the treatment group were po administered with Gongliuxiao Capsules on the basis of the control group, 4 grains/time, three times daily. The patients in two groups were treated for 6 months. After treatment, the efficacy was evaluated, and the changes of uterine volume, fibroid volume, FSH, P, E₂, and LH in two groups were compared. Results After treatment, the efficacies in the control and treatment groups were 80.36% and 91.07%, respectively, and there were differences between two groups (P < 0.05). After treatment, uterine volume, fibroid volume, E₂, P, and FSH in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). After treatment, the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P < 0.05). Conclusion Gongliuxiao Capsules combined with methyltestosterone and mifepristone has clinical curative effect in treatment of menopause uterine fibroids, and can significantly reduce fibroid volume, also can lower the levels of E₂, P, and FSH, which has a certain clinical application value.